LeMaitre Vascular (NASDAQ:LMAT) Releases Quarterly Earnings Results, Hits Expectations

LeMaitre Vascular (NASDAQ:LMAT) released its earnings results on Thursday. The medical instruments supplier reported $0.49 earnings per share for the quarter, hitting the consensus estimate of $0.49, Zacks reports. The company had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular updated its FY 2025 guidance to 2.150-2.320 EPS and its Q1 2025 guidance to 0.480-0.530 EPS.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $99.91 on Friday. LeMaitre Vascular has a one year low of $62.39 and a one year high of $109.58. The company has a 50-day simple moving average of $96.90 and a 200-day simple moving average of $94.66. The firm has a market capitalization of $2.25 billion, a PE ratio of 54.60, a price-to-earnings-growth ratio of 2.22 and a beta of 0.96.

Analyst Ratings Changes

LMAT has been the subject of several research analyst reports. Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price for the company. Oppenheimer downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday. Five analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $94.63.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.